Drug Profile
Research programme: anti-inflammatory polysaccharides - Verona
Alternative Names: NAIPSLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Verona Pharma
- Developer GlycoMar; Verona Pharma
- Class Polysaccharides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic rhinitis; Asthma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Allergic-rhinitis in United Kingdom
- 04 Nov 2017 No recent reports of development identified for research development in Asthma in United Kingdom
- 22 Apr 2013 Early research is ongoing in United Kingdom